Product Description
The research-grade biosimilar is a fully human anti-IL-6R monoclonal IgG1 antibody that can bind to membrane as well as soluble forms of interleukin 6 receptor (IL-6R). This leads to inhibition of IL-6 mediated signaling and reduced release of CRP, serum amyloid A and fibrinogen, which are potential biomarkers of rheumatoid arthritis (RA). The original monoclonal antibody received US-FDA approval in 2017 to treat moderate to severe RA in combination with methotrexate. The original antibody is currently being evaluated for phase 3 clinical trial on COVID-19 patients
Biovision | A2133 | Anti-IL-6R? (Sarilumab), Human IgG1 Antibody DataSheet
Antibody Target: PD-1
Target Alternative Name: IL6Q, gp80, CD126, IL6RA, IL6RQ, IL-6RA, IL-6R-1, HIES5, IL-6R, IL-1Ra, IL6QTL, IL-6R-Alpha, IL6R, IL-6R 1
Tag Line: A fully human anti-IL-6R? monoclonal antibody that binds membrane-bound and soluble human IL-6R? with high affinity
Category: Primary antibody
Host: Recombinant
Isotype: Human IgG1
Species Reactivities:
Immunogen Sequence: Sarilumab
Accession #:
Gene ID: 3570
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS buffer, pH 7.2
Purification:
Application: In vitro and In vivo studies
Positive Control:
Application And Usages: In vitro and In vivo studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE